MANNKIND CORP Selling, General and Administrative Expense
MANNKIND CORP (MNKD) reported Selling, General and Administrative Expense of $58.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- MANNKIND CORP selling, general and administrative expense for the quarter ending 2026-06-30 was $58.30M, a 84.37% increase year-over-year.
- MANNKIND CORP selling, general and administrative expense for the quarter ending 2026-03-31 was $54.09M, a 116.22% increase year-over-year.
- MANNKIND CORP selling, general and administrative expense for the quarter ending 2025-12-31 was $58.41M, a 143.66% increase year-over-year.
- MANNKIND CORP selling, general and administrative expense for the quarter ending 2025-09-30 was $29.09M, a 21.63% increase year-over-year.
- MANNKIND CORP selling, general and administrative expense for fiscal 2025 was $144.13M, a 52.80% increase from fiscal 2024.
- MANNKIND CORP selling, general and administrative expense for fiscal 2024 was $94.33M, a 0.02% increase from fiscal 2023.
- MANNKIND CORP selling, general and administrative expense for fiscal 2023 was $94.31M, a 3.11% increase from fiscal 2022.
- MANNKIND CORP selling, general and administrative expense for fiscal 2022 was $91.47M, a 18.16% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.30M 10-Q · filed 2026-08-05 | $112.39M 10-Q · filed 2026-08-05 | $170.80M derived: sum of 3 quarters · filed 2026-08-05 | $199.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $54.09M 10-Q · filed 2026-05-06 | $112.50M derived: sum of 2 quarters · filed 2026-05-06 | $141.58M derived: sum of 3 quarters · filed 2026-05-06 | $173.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $58.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $87.50M derived: sum of 2 quarters · filed 2026-02-26 | $119.12M derived: sum of 3 quarters · filed 2026-08-05 | $144.13M 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.09M 10-Q · filed 2025-11-05 | $60.71M derived: sum of 2 quarters · filed 2026-08-05 | $85.72M 10-Q · filed 2025-11-05 | $109.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $31.62M 10-Q · filed 2026-08-05 | $56.64M 10-Q · filed 2026-08-05 | $80.61M derived: sum of 3 quarters · filed 2026-08-05 | $104.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $25.01M 10-Q · filed 2026-05-06 | $48.99M derived: sum of 2 quarters · filed 2026-05-06 | $72.90M derived: sum of 3 quarters · filed 2026-05-06 | $97.01M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $23.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.89M derived: sum of 2 quarters · filed 2026-02-26 | $72.00M derived: sum of 3 quarters · filed 2026-02-26 | $94.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | $23.92M 10-Q · filed 2025-11-05 | $48.03M derived: sum of 2 quarters · filed 2025-11-05 | $70.36M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $24.11M 10-Q · filed 2025-08-06 | $46.44M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $22.33M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $94.31M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $44.73M derived: sum of 2 quarters · filed 2025-02-26 | $70.78M derived: sum of 3 quarters · filed 2025-02-26 | $91.47M 10-K · filed 2025-02-26 |
| 2022-09-30 | $22.64M 10-Q · filed 2022-11-08 | $48.68M derived: sum of 2 quarters · filed 2022-11-08 | $69.38M 10-Q · filed 2022-11-08 | $92.11M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | $26.04M 10-Q · filed 2022-08-09 | $46.74M 10-Q · filed 2022-08-09 | $69.47M derived: sum of 3 quarters · filed 2022-08-09 | $86.69M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-03-31 | $20.70M 10-Q · filed 2022-05-05 | $43.42M derived: sum of 2 quarters · filed 2022-05-05 | $60.65M derived: sum of 3 quarters · filed 2022-11-08 | $80.70M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-12-31 | $22.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $39.95M derived: sum of 2 quarters · filed 2022-11-08 | $60.00M derived: sum of 3 quarters · filed 2022-11-08 | $77.42M 10-K · filed 2022-02-24 |
| 2021-09-30 | $17.22M 10-Q · filed 2022-11-08 | $37.28M derived: sum of 2 quarters · filed 2022-11-08 | $54.69M 10-Q · filed 2022-11-08 | $71.81M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $20.06M 10-Q · filed 2022-08-09 | $37.47M 10-Q · filed 2022-08-09 | $54.59M derived: sum of 3 quarters · filed 2022-08-09 | $68.49M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $17.41M 10-Q · filed 2022-05-05 | $34.53M derived: sum of 2 quarters · filed 2022-05-05 | $48.43M derived: sum of 3 quarters · filed 2022-05-05 | $62.10M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $17.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $31.02M derived: sum of 2 quarters · filed 2022-02-24 | $44.69M derived: sum of 3 quarters · filed 2022-02-24 | $59.04M 10-K · filed 2022-02-24 |
| 2020-09-30 | $13.90M 10-Q · filed 2021-11-09 | $27.57M derived: sum of 2 quarters · filed 2021-11-09 | $41.92M 10-Q · filed 2021-11-09 | $57.64M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $13.67M 10-Q · filed 2021-08-11 | $28.02M 10-Q · filed 2021-08-11 | $43.74M derived: sum of 3 quarters · filed 2021-08-11 | $60.41M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $14.35M 10-Q · filed 2021-05-12 | $30.07M derived: sum of 2 quarters · filed 2021-05-12 | $46.74M derived: sum of 3 quarters · filed 2021-05-12 | $63.35M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $15.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $32.39M derived: sum of 2 quarters · filed 2021-02-25 | $49.00M derived: sum of 3 quarters · filed 2021-02-25 | $74.67M 10-K · filed 2021-02-25 |
| 2019-09-30 | $16.67M 10-Q · filed 2020-11-04 | $33.27M derived: sum of 2 quarters · filed 2020-11-04 | $58.95M 10-Q · filed 2020-11-04 | $76.92M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $16.61M 10-Q · filed 2020-08-05 | $42.28M 10-Q · filed 2020-08-05 | $60.26M derived: sum of 3 quarters · filed 2020-08-05 | $79.65M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $25.67M 10-Q · filed 2020-05-06 | $43.65M derived: sum of 2 quarters · filed 2020-05-06 | $63.04M derived: sum of 3 quarters · filed 2020-05-06 | $84.77M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $17.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $37.37M derived: sum of 2 quarters · filed 2020-02-25 | $59.10M derived: sum of 3 quarters · filed 2020-02-25 | $79.72M 10-K · filed 2020-02-25 |
| 2018-09-30 | $19.39M 10-Q · filed 2019-11-08 | $41.13M derived: sum of 2 quarters · filed 2019-11-08 | $61.74M 10-Q · filed 2019-11-08 | $85.02M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $21.73M 10-Q · filed 2019-08-07 | $42.35M 10-Q · filed 2019-08-07 | $65.63M derived: sum of 3 quarters · filed 2019-08-07 | $83.35M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $20.62M 10-Q · filed 2019-05-07 | $43.90M derived: sum of 2 quarters · filed 2019-05-07 | $61.62M derived: sum of 3 quarters · filed 2019-05-07 | $80.19M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $23.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $41.00M derived: sum of 2 quarters · filed 2019-02-26 | $59.57M derived: sum of 3 quarters · filed 2019-02-26 | $74.96M 10-K · filed 2019-02-26 |
| 2017-09-30 | $17.73M 10-Q · filed 2018-11-01 | $36.29M derived: sum of 2 quarters · filed 2018-11-01 | $51.68M 10-Q · filed 2018-11-01 | $67.01M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $18.57M 10-Q · filed 2018-08-02 | $33.96M 10-Q · filed 2018-08-02 | $49.29M derived: sum of 3 quarters · filed 2019-02-26 | $62.42M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $15.39M 10-Q · filed 2018-05-09 | $30.72M derived: sum of 2 quarters · filed 2019-02-26 | $43.86M derived: sum of 3 quarters · filed 2019-02-26 | $54.97M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $28.47M derived: sum of 2 quarters · filed 2019-02-26 | $39.58M derived: sum of 3 quarters · filed 2019-02-26 | $46.93M 10-K · filed 2019-02-26 |
| 2016-09-30 | $13.13M 10-Q · filed 2017-11-07 | $24.25M derived: sum of 2 quarters · filed 2017-11-07 | $31.59M 10-Q · filed 2017-11-07 | $39.91M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $11.11M 10-Q · filed 2017-08-07 | $18.46M 10-Q · filed 2017-08-07 | $26.77M derived: sum of 3 quarters · filed 2018-02-27 | $38.32M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $7.35M 10-Q · filed 2017-05-10 | $15.66M derived: sum of 2 quarters · filed 2018-02-27 | $27.21M derived: sum of 3 quarters · filed 2018-02-27 | $37.83M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $19.86M derived: sum of 2 quarters · filed 2018-02-27 | $30.48M derived: sum of 3 quarters · filed 2018-02-27 | $40.96M 10-K · filed 2018-02-27 |
| 2015-09-30 | $11.55M 10-Q · filed 2016-11-09 | $22.17M derived: sum of 2 quarters · filed 2016-11-09 | $32.65M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $10.62M 10-Q/A · filed 2016-08-10 | $21.10M 10-Q/A · filed 2016-08-10 | ||
| 2014-12-31 | $79.38M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |